Skip to main content
Clinical Trials/NL-OMON44886
NL-OMON44886
Completed
Not Applicable

The attenuation coefficient of the retinal nerve fiber layer derived from spectral domain optical coherence tomography AND diplopia in Parkinson*s disease - New OCT technique and diplopia in Parkinson's disease

Vrije Universiteit Medisch Centrum0 sites100 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Parkinson's disease
Sponsor
Vrije Universiteit Medisch Centrum
Enrollment
100
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational non invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • In order to be eligible to participate in this study, a patient must meet all of the following criteria:
  • \- Clinical diagnosis of PD fulfilling the criteria of the UK PD Brain Bank (METC protocol, appendix B)
  • \- (modified) Hoehn and Yahr stage 2 \- 4 (METC protocol, appendix C) and a follow up of at least three years after diagnosis of PD.
  • \- Age 50 \- 70 years
  • \- Best\-corrected vision 20/30 or higher (using a Snellen chart)
  • \- Intra\-ocular pressure \< 21 mmHg to rule out glaucoma;In order to be eligible to participate in this study, a control subject must meet all of the following criteria:
  • \- Best\-corrected vision 20/30 or higher (using a Snellen chart)
  • \- Intra\-ocular pressure \< 21 mmHg to rule out glaucoma

Exclusion Criteria

  • A potential subject who meets any of the following criteria will be excluded from participation in this study:
  • \- Media opacifications
  • \- Concomitant ocular disease (glaucoma, retinal pathology, or pathology of the cornea, lens or optic nerve)
  • \- History of ocular trauma
  • \- History of laser therapy
  • \- Degenerative neurological disease other than PD.
  • \- MMSE \< 26 in healthy controls (this is a possible indication of a degenerative neurological disease)
  • \- First degree relative with PD

Outcomes

Primary Outcomes

Not specified

Similar Trials